You are here

  • Home
  • Archive
  • Volume 22, Issue Suppl 1
  • CP-061 Long-term cost-effectiveness analysis of infliximab, etanercept and adalimumab in rheumatoid arthritis patients in real-life clinical practice

Article info

Article menu
Download PDFPDF
Clinical pharmacy
CP-061 Long-term cost-effectiveness analysis of infliximab, etanercept and adalimumab in rheumatoid arthritis patients in real-life clinical practice

Authors

Citation

Cardenas M, Font P, De La Fuente-Ruiz S, et al
CP-061 Long-term cost-effectiveness analysis of infliximab, etanercept and adalimumab in rheumatoid arthritis patients in real-life clinical practice
European Journal of Hospital Pharmacy 2015;22:A24.

Publication history

  • First published March 24, 2015.
Online issue publication 
May 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions